Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
2023年2月22日 · Here, we report the safety and efficacy of etranacogene dezaparvovec from Health Outcomes with Padua Gene; Evaluation in Hemophilia B (HOPE-B), a phase 3 study of …
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B…
We report post-hoc 24-month efficacy and safety data from this trial to evaluate the longer-term effects of etranacogene dezaparvovec in individuals with haemophilia B.
First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy …
2020年11月19日 · Methods: HOPE-B is a Phase 3, open-label, single-dose, single-arm, multi-national trial in adult males with severe or moderate-severe HB (FIX≤2%). All pts received …
Hemgenix Gene Therapy Benefits Sustained for 2 Years in Phase 3...
2022年12月14日 · These findings from the pivotal HOPE-B trial (NCT03569891) supported the U.S. Food and Drug Administration’s recent approval of the therapy for adult hemophilia B …
Breaking ground in haemophilia B gene therapy: insights from the HOPE-B …
2024年3月1日 · Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
Hope on B&B — Everything You Need to Know | Soaps In Depth
2024年12月23日 · Who plays Hope on The Bold and The Beautiful? How many Hopes have there been on B&B? What happened to Hope? We've got answers!
New HOPE for Hemophilia B: One-Time Gene Therapy Abolishes Bleeding in ...
A single dose of the gene therapy drug etranacogene dezaparvovec increased factor IX (FIX) activity levels, and eliminated the need for prophylactic FIX, in patients with severe to …
Adults with Severe or Moderately Severe Hemophilia B Receiving ...
2022年11月15日 · The Phase 3 HOPE-B clinical trial (NCT03569891) of etranacogene dezaparvovec met its primary efficacy endpoint, providing hemostatic protection superior to …
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B…
2024年3月1日 · The HOPE-B trial shows that etranacogene dezaparvovec can provide durable disease correction throughout 24 months after gene therapy in men with severe or moderately …
CSL Reports Positive Final Analysis of Pivotal HOPE-B Study of …
2022年2月7日 · CSL Behring reported positive long-term results from the phase 3 HOPE-B clinical trial evaluating etranacogene dezaparvovec, an investigational AAV5-based gene …